Chinese Companies Progress Peptide Fusion Inhibitors For COVID-19

 
• By Dexter Jie Yan

China's Hybio, Youcare and Shanxi Jinbo appear to be the only three companies in the world trying to develop a fusion inhibitor for COVID-19, the most advanced of which has now moved into a domestic Phase II trial.

nasal spray
Chinese firm working on nasal spray for pre-exposure prophylaxis of COVID-19 • Source: Shutterstock

More from China

More from Focus On Asia